Bayer acquires rights to Cytokinetics' heart drug in Japan [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
experimental heart drug, as the German group strengthens its cardiovascular business with smaller deals. Cytokinetics will receive 50 million euros ($53 million) upfront, plus up to 90 million euros contingent on certain development achievements, Bayer said in a statement. Cytokinetics also stands to receive up to 490 million euros from Bayer, depending on certain sales milestones. The deal covers certain uses of drug candidate aficamten in hypertrophic cardiomyopathy, an inherited condition that limits the heart's pumping function. German diversified group Bayer, which is burdened by debt, weak agriculture markets and costly litigation, has faced investor calls to boost its drug development pipeline. In March, Bayer acquired European commercialization rights for heart drug acoramidis for up to $310 million from a group of companies. ($1 = 0.9448 euros) (Reporting by Ludwig Burger, Editing by Friederike Heine)
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.MarketBeat
- Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan [Yahoo! Finance]Yahoo! Finance
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.MarketBeat
- Cytokinetics and Bayer partner to develop for aficamten in Japan [Seeking Alpha]Seeking Alpha
- Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]Yahoo! Finance
CYTK
Earnings
- 11/6/24 - Miss
CYTK
Sec Filings
- 11/19/24 - Form 4
- 11/19/24 - Form 8-K
- 11/18/24 - Form 144
- CYTK's page on the SEC website